Infertility, Female Clinical Trial
Official title:
A Randomized Controlled Study on Sequential Therapy of Kidney Tonifying and Blood Regulating Herbs to Improve the Success Rate of IVF-ET in Patients With Ovarian Reserve Dysfunction
In the early stage, our team found that traditional Chinese medicine (TCM) intervention aimed at Nourishing kidney and regulating blood circulation in vitro fertilization and embryo transfer(IVF-ET) can improve the clinical pregnancy rate. In order to further study the role of TCM in improving the pregnancy outcome of IVF-ET in infertility due to decreased ovarian reserve (DOR). A randomized controlled clinical trial was used in this study. 200 infertile patients with DOR were randomly divided into two groups. The control group was treated with conventional modern medicine, and the treatment group was treated with traditional Chinese herbs on the basis of conventional modern medicine. The intervention started from the 5th day of the first menstrual cycles after enrollment and lasted for three months before IVF-ET. After the transplantation, the TCM treatment continues for 14 days. The number of oocytes, antral follicles, anti-Mullerian hormone(AMH), serum follicle-stimulating hormone(FSH), and clinical pregnancy rate will be observed to evaluate the effect of traditional Chinese medicine on the improvement of ovarian function, pregnancy outcome, and fertility of DOR patients.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | December 30, 2022 |
Est. primary completion date | December 30, 2022 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 20 Years to 40 Years |
Eligibility | Inclusion Criteria: 1. Consent to participate in this clinical trial and sign an informed consent form. 2. Age =40 years, regular menstrual cycle between 21and 35 days in length. 3. Meet the Western diagnostic criteria for DOR. 4. Meet the criteria for identifying kidney deficiency in Chinese medicine. 5. Planning to undergo IVF-ET for pregnancy. Exclusion Criteria: 1. History of two or more previous spontaneous abortions (excluding biochemical pregnancy abortions) or three or more previous ETs without obtaining a clinical pregnancy. 2. Premature ovarian failure or ovarian gonadotropin resistance syndrome. 3. Untreated uterine anomalies or abnormalities, including double uterus or longitudinal uterus (complete or incomplete). 4. Untreated hydrocele on one or both fallopian tubes (confirmed by hysterosalpingography). 5. Uterine adhesions, endometriosis, adenomyosis, endometrial lesions (submucosal fibroids, endometrial polyps, etc.), or uterine fibroids >4 cm. 6. Endocrine disorder affecting ovulation, such as polycystic ovary syndrome, hyperprolactinaemia, hyperandrogenaemia, hypothyroidism, or adrenal abnormalities. 7. Infertility with abnormal ovarian function due to immune factors, genetic factors, or congenital physical defects. 8. Previous pelvic radiotherapy. 9. Known or suspected sex hormone-related malignancy. 10. Allergy to or intolerance of the drugs used in the study. 11. Combined contraindications to assisted reproductive technology or pregnancy, such as uncontrolled abnormalities of liver and kidney function, diabetes mellitus (glycosylated haemoglobin =7%, fasting blood glucose <10 mmol/L ), hypertension, thyroid disease, symptomatic heart disease, moderate to severe anaemia, history of malignancy or thromboembolism or propensity to thrombosis, severe psychiatric disorder, acute infections of the genitourinary system, sexually transmitted diseases, serious adverse habits such as drug abuse, exposure to teratogenic amounts of radiation, toxins, or drugs (such as prednisone or other hormones, adrenaline, antibiotics, or hypertension, cardiovascular, or antiviral medications) during the active procedure period , and uterine factor infertility or physical illness which prevents the ability to bear a pregnancy. |
Country | Name | City | State |
---|---|---|---|
China | Peking University Third Hospital | Beijing, China |
Lead Sponsor | Collaborator |
---|---|
Peking University Third Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of eggs obtained | Obtained by blood sampling before the proposed IVF-ET | up to 15 weeks from enrollment | |
Primary | Change from Baseline concentration of Serum anti-Mullerian hormone(AMH) before the proposed IVF-ET | Obtained by blood sampling before taking TCM herbs and before the proposed IVF-ET | The 5th day of menstruation in the month of enrollment and Before the proposed IVF-ET(up to 15 weeks from the enrollment) | |
Primary | Change from Baseline concentration of Serum follicle-stimulating hormone (FSH) before the proposed IVF-ET | Obtained by blood sampling before taking TCM herbs and before the proposed IVF-ET | The 5th day of menstruation in the month of enrollment and Before the proposed IVF-ET(up to 15 weeks from the enrollment) | |
Primary | Clinical pregnancy rate (%): number of clinical pregnancies/total number of ET cycles | Follow up by telephone calls 30days after the IVF-ET | up to 19 weeks from the enrollment | |
Secondary | Change from Baseline concentration of antral follicle count(AFC) before the proposed IVF-ET | Obtained by blood sampling before taking TCM herbs and before the proposed IVF-ET | The 5th day of menstruation in the month of enrollment and Before the proposed IVF-ET(up to 15 weeks from the enrollment) | |
Secondary | Concentration of follicular E2 level on the day of human chorionic gonadotropin(hCG) injection | Obtained by blood sampling before the proposed IVF-ET | up to 15 weeks from enrollment | |
Secondary | Change from Baseline concentration of Serum luteinising hormone(LH) before the proposed IVF-ET | Obtained by blood sampling before taking TCM herbs and before the proposed IVF-ET | The 5th day of menstruation in the month of enrollment and Before the proposed IVF-ET(up to 15 weeks from the enrollment) | |
Secondary | Quality egg rate (%) | Before the proposed IVF-ET | up to 15 weeks from enrollment | |
Secondary | Total amount of ovulation-promoting drugs | Before the proposed IVF-ET | up to 15 weeks from enrollment | |
Secondary | Fertilisation rate (%) | Before the proposed IVF-ET | up to 15 weeks from enrollment | |
Secondary | Implantation rate (%): number of gestational sacs/number of embryos transferred | 30days after the IVF-ET | up to 19 weeks from the enrollment | |
Secondary | Concentration of human chorionic gonadotropin(hCG) | 14days after the IVF-ET | up to 17 weeks from the enrollment | |
Secondary | Concentration of progesterone | 14days after the IVF-ET | up to 17 weeks from the enrollment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05969574 -
Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages?
|
||
Recruiting |
NCT05358483 -
PROspective Study of Mothers' and Infants' Social and Epidemiologic Determinants of Health
|
||
Recruiting |
NCT05969795 -
Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support
|
Phase 1 | |
Recruiting |
NCT06051201 -
Innovation for Small-scale Experiments: ReceptIVFity Test
|
N/A | |
Completed |
NCT03177538 -
Corifollitropin Alfa Combined With Menotropin Versus Follitropin and Lutropin Alfa in Expected Suboptimal Responders
|
Phase 4 | |
Completed |
NCT03638856 -
Comparing Effectiveness of Oral Misoprostal for Cervical Priming in Hysteroscopy
|
N/A | |
Completed |
NCT04052464 -
The Study of the Implantation Window From Endometrial Biopsy With Gene Expression Methods
|
||
Withdrawn |
NCT04753736 -
Immunophenotypage of RIF and RM Patients and Intrauterine Administration of PBMC
|
N/A | |
Completed |
NCT03349905 -
Deferred Versus Fresh Embryo Transfers
|
N/A | |
Completed |
NCT05076981 -
Progesterone Levels During Ovulation and Luteal Phase
|
||
Completed |
NCT04096027 -
Cabergoline Before or After Oocyte Collection for Follicular Resolution
|
Phase 4 | |
Recruiting |
NCT05980091 -
Optimal Timing of Euploid Day 6 Blastocyst Transfer in Frozen HRT Cycles, Day 6 or Day 7 of Progesterone Administration.
|
Phase 1 | |
Terminated |
NCT01933633 -
Improved Fertility After Exercise in Overweight/Obese Women
|
N/A | |
Completed |
NCT01202656 -
Effect of Colony Stimulating Factor on Implantation and Pregnancy Rates Following IVF (in Vitro Fertilization)
|
Phase 1/Phase 2 | |
Terminated |
NCT01202643 -
Effect of Colony Stimulating Factor on Poor Endometrial Development During IVF
|
Phase 1/Phase 2 | |
Completed |
NCT01408615 -
A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)
|
||
Enrolling by invitation |
NCT05698550 -
The Role of Erzhi Tiangui Formula in Expected POR Women Undergoing IVF-ET
|
Phase 3 | |
Not yet recruiting |
NCT03910582 -
Personalized FET in RIF Patients With Displaced Dating
|
N/A | |
Completed |
NCT05440019 -
Evaluation of the Safety and Usability of the M3T Fertigo System and Its Calibration
|
||
Completed |
NCT05130125 -
Retrospective Cohort Observational Study to Evaluate the Effectiveness and Safety of Fresh or Frozen Embryo Transfer
|